Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
62 results about "Bufalin" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Bufalin, is a cardiotonic steroid originally isolated from the Chinese toad venom. It is a component found in many Chinese traditional medicine.
Toad sterene compounds and application thereof in pharmaceutical preparation
ActiveCN101016326AInhibitory activityGood water solubilityAntiviralsPill deliveryCancer cellMedicine
Owner:ANHUI CHINA RESOURCES JINCHAN PHARMA CO LTD
Bufalin derivative as well as preparation method, pharmaceutical composition and application thereof
ActiveCN103570792AEasy to synthesizeEasy to manufactureOrganic active ingredientsSteroidsPharmaceutical drugPharmaceutical medicine
The invention relates to a bufalin derivative having a structure represented as a general formula I, wherein R is selected from one of the following structure groups as shown in the specification, or pharmaceutically acceptable salt, as well as a preparation method, a pharmaceutical composition and application of the derivative. The bufalin derivative has an activity on inhibiting tumor cell lines, and can be used as a medicine for treating malignant tumors.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Traditional Chinese medicine venenum bufonis extract and preparation method thereof
ActiveCN102512453AImprove extraction efficiencyExcellent transfer rateAmphibian material medical ingredientsAntineoplastic agentsMedicinal herbsGradient elution
The invention relates to a traditional Chinese medicine venenum bufonis extract. A method for extracting the extract includes steps of extracting traditional Chinese venenum bufonis medical materials at the temperature ranging from 60 DEG C to 90 DEG C by ethanol water with volume percent of 60-95% in a backflow manner, separating extract liquid via silicagel columns after the extract liquid is concentrated, adopting petroleum ether and acetone with volume ratio of 1-8:1 as eluant to realize gradient elution, collecting parts of eluent, and filtering, concentrating and drying the eluent in a pressure reduction manner to obtain the traditional Chinese medicine vanenum bufonis extract containing mixture of three types of bufotalin including resibufogenin, cinobufagin and bufalin, wherein the sum of the weight percentages (calculated when three types of the bufotalin are dried) of the three types of the bufotalin is higher than or equal to 95%. The invention further provides the preparation method for the traditional Chinese medicine venenum bufonis extract. The sum of the weight percentages of the three types of the bufotalin in the traditional Chinese medicine venenum bufonis extract is higher than 95%, extraction transfer rate is high, the quantity of used solvent is lower, residual solvent is little, pollution degree is lower, operation is simple and convenient, and industrial production is realized easily.
Owner:北京协和制药二厂有限公司
Bufalin derivatives, pharmaceutical compositions and methods thereof
ActiveCN103980337AOrganic active ingredientsPharmaceutical delivery mechanismPharmaceutical SubstancesOrganic chemistry
Owner:SUZHOU NEUPHARMA CO LTD
Traditional Chinese medicine toad venom dissimlar extract and preparation method thereof
InactiveCN104840488AHigh yieldStable indicator component transfer rateAmphibian material medical ingredientsAntineoplastic agentsMedicinal herbsToad Venom
The invention relates to a traditional Chinese medicine toad venom dissimlar extract and a preparation method thereof, and belongs to the technical field of drugs. The preparation method of the extract comprises the steps of crushing toad venom medicinal materials into middle power, and adding 4 to 10 times of water for grinding and dispersing; adding ethyl alcohol to carry out alcohol precipitation, and storing at a low temperature; adding sodium chloride into supernatant liquor for salting out at a low temperature; carrying out concentration under reduced pressure until block-shaped toad venom dissimlar extract is separated out, carrying out drying or concentration under reduced pressure until nearly dry, carrying out vacuum drying, and adding ethanol recrystallization, so as to obtain the toad venom dissimlar extract containing resibufogenin, cinobufagin venom toad and bufalin; the transfer rate of the mixture of three bufogenins is about 80%, and the sum of weight percentages of the three bufogenins is equal to or greater than 35%. The toad venom extracted by adopting the method has the advantages of high transfer rate and active ingredient content, no residual organic solvent, simple and convenient operation, low energy consumption, and easiness in controlling of product quality, and is suitable for industrializing production.
Owner:INNER MONGOLIA CONBA PHARMA CO LTD
Purifying technology for lipid bufalin genin and cino-bufagin in fresh senso
The present invention discloses the technology of purifying lipid bufogenin and cino-bufogenin in fresh toad cake. The purifying process includes grinding fresh toad cake, adding organic solvent through stirring to obtain toad cake solution, standing, filtering to obtain filtrate, concentrating and drying to obtain the product. The toad cake powder product has relatively high lipid bufogenin and cino-bufogenin content.
Owner:王利忠
Tumor targeted prodrug having endosome escaping function as well as nano preparation and preparation method of tumor targeted prodrug
InactiveCN105168230AEasy to prepareSuitable for mass productionOrganic active ingredientsPharmaceutical non-active ingredientsTumor targetCancer cell
The invention provides a tumor targeted prodrug having an endosome escaping function; the tumor targeted prodrug is P (OEGMA-co-BUF-co-RGD)-g-P (DEA-co-BMA), wherein POEGMA is a water-soluble polymer having a long circulation function, BUF is chemotherapeutic bufalin having an antineoplastic activity, cRGD is polypeptide capable of targeting tumor tissues actively and P (DEA-co-BMA) is a polymer having an endosome escaping function. The invention also provides a method for preparing the tumor targeted prodrug, as well as a nano preparation and a preparation method of the tumor targeted prodrug having the endosome escaping function. The nano preparation can be used for effectively killing cancer cells with a relatively low dosage; and an effect of killing various cancer cells is obviously better than that of a free bufalin medicine.
Owner:SHANGHAI PUTUO DISTRICT CENT HOSPITAL
Application of bufotoxin extract in preparation of medicine for treating human brain glioma
InactiveCN105687251AAntitumor effect is obviousGood treatment effectAmphibian material medical ingredientsOrganic active ingredientsSide effectHuman glioma
The present invention discloses the application of toad venom extract containing more than 90% of bufolin, cinobufagin and cinobufagin in the preparation of medicines for treating human glioma. The content ratio of tobafagenin is 2:3:5, and the extract of toad venom is prepared into a nano-preparation. The bufagenin nano-preparation of the invention can increase the distribution of bufagenin in the brain and avoid being taken up by the heart, thereby improving the brain-targeting property of the drug and reducing cardiotoxicity. Compared with the common extract solution of bufogenin, the nano-preparation of bufogenin has a stronger therapeutic effect on glioma brain and less side effects, thus enhancing the use value of bufogenin and providing a new method for the treatment of glioma. new drug.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Bufalin-loaded polypeptide-modified poly(oligo(ethylene glycol)methacrylate)-polycaprolactone (Ph PCL b P(OEGMA co RGD) bufalin) nanometer preparation
InactiveCN105709231AEasy to prepareSuitable for mass productionPharmaceutical non-active ingredientsEmulsion deliveryMethacrylateCyclic peptide
The invention belongs to the technical field of a tumor targeting deliverying and slow release administration system. The invention relates to a bufalin-loaded valine-arginine-glycine-aspartic acid-glutamic acid cyclopeptide (cRGD)-modified poly(oligo(ethylene glycol)methacrylate)-polycaprolactone (Ph PCL b P(OEGMA co RGD) bufalin) nanometer particle and a preparation method thereof. Ph-PCL-b-P(OEGMA-co-GMA) as a base material is modified through cRGD to form Ph-PCL-b-P(OEGMA-co-RGD) and bufalin is wrapped by micelle of the Ph-PCL-b-P(OEGMA-co-RGD) so that (Ph PCL b P(OEGMA co RGD) bufalin) nanometer particles are prepared. The nanometer preparation can effectively reduce toxic or side effect of bufalin and improve water solubility and tumor targeting ability. The bufalin is slowly released along with material degradation so that long-term treatment effects are obtained.
Owner:SHANGHAI UNIV OF TRADITIONAL CHINESE MEDICINE PUTUO DISTRICT CENT HOSPITAL
Bufalin liposome, preparation method therefor and application thereof
ActiveUS20150328234A1Good treatment effectImprove packaging efficiencyOrganic active ingredientsPill deliveryPancreas CancersSterol
The present invention provides a bufalin liposome comprising a liposome bilayer and bufalin. The liposome bilayer comprises phospholipid, sterol and polyethylene glycol (PEG)-derived compound. The liposome of the present invention can be used to treat cancer, especially a cancer chosen from liver cancer, lung cancer, ovarian cancer, prostate cancer, colon cancer, pancreas cancer, gastric cancer, and leukemia. The preparation method of the present invention is simple, and the bufalin liposome can increase an effect of antitumor, reduce a toxicity compared with bufalin monomer, and has wide applications.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Medicine containing toad venom lipid-soluble substances and preparation method thereof
InactiveCN105125592AReduce direct stimulationLow toxicityAmphibian material medical ingredientsAntipyreticWater bathsToad Venom
The invention provides medicine containing toad venom lipid-soluble substances and a preparation method thereof. According to the toad venom lipid-soluble substances, the weight sum of bufalin, cinobufagin and resibufogenin is larger than 50% of the total weight of the toad venom lipid-soluble substances. The preparation method of the toad venom lipid-soluble substances includes the steps that toad venom herbs are smashed, then absolute ethyl alcohol is added, the amount of the absolute ethyl alcohol is 5-50 times that of the herbs, heating reflux is performed on the mixture for 1 h in a water bath of 60 DEG C, then the mixture is cooled to indoor temperature, suction filtration is performed, dry extract is obtained after filtrate is evaporated to dryness, purified water is added into the extract for ultrasonic suspending, the amount of the purified water is 5-30 times that of the extract, and extracting is performed through chloroform, wherein the amount of chloroform is 5-50 times that of the mixture. The invention further provides a medicine composite and a preparation method thereof. The medicine composite is a toad venom extract lipid microsphere oral solution and is used for treating gastrointestinal tumors.
Owner:NKD PHARMA CO LTD
Glycosylated derivatives of bufolin and its preparation method and application in the preparation of antitumor drugs
ActiveCN103288911BSmall toxicityImprove anti-tumor activitySteroidsAntineoplastic agentsSolubilityKetone
The invention discloses a bufalin glycosylation derivative and a preparation method and application thereof in preparation of anti-tumour medicaments. The structure of the bufalin glycosylation derivative is shown in a formula I or formula II. The synthesis method of the bufalin glycosylation derivative comprises the following steps of: oxidizing bufalin into a ketone-form derivative by pyridinium chloropyridine hydrochloride; then performing a nucleophilic addition reaction with methoxyamine hydrochloride; removing monomolecular water to generate an oxime-form intermediate; enabling the oxime-form intermediate to react with a tert-butylamine borane hydrochloride compound to generate alpha-configuration aglycone and beta-configuration aglycone; and finally enabling the aglycones of two configurations to react with reducing sugar respectively to generate the bufalin glycosylation derivative. According to the method disclosed by the invention, bufalin is modified to be the glycosylation derivative thereof, and the water solubility can be improved while the anti-tumour activity is kept and enhanced; and moreover, in-vivo experiments prove that the toxic and side effects of the bufalin glycosylation derivative disclosed by the invention on normal cells are reduced compared with those of a parent compound of bufalin.
Owner:GUANGXI WUZHOU PHARMA GRP
Lung cancer and breast cancer treatment compound preparation containing active ingredients of traditional Chinese medicine and preparation method of lung cancer and breast cancer compound preparation
InactiveCN105079005AGood inhibitory effectHigh anticancer activityEther/acetal active ingredientsRespiratory disorderPolyethylene glycolIn vivo
Owner:NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Bufalin dry powder inhalant as well as preparation method and application thereof
ActiveCN102247335AIncrease surface areaBig effectPowder deliveryOrganic active ingredientsSide effectOral medication
The invention relates to a dry powder inhalant, in particular to a Bufalin dry powder inhalant, the preparation method of the dry powder inhalant and the application in preparing drug for treating lung tumors. The Bufalin dry powder inhalant is characterized in that the Bufalin dry powder inhalant is composed of Bufalin and pharmaceutically acceptable auxiliary materials, wherein the mass ratio of the Bufalin to pharmaceutically acceptable auxiliary materials is (1:0.01)-(1:110). The dry powder inhalant by taking the Bufalin as the main drug can directly act on an affected part by aiming at the lung tumor to lower the possibility of toxic and side effect and improve the bioavailability. According to the Bufalin dry powder inhalant, the defects that the oral-administration preparation slowly takes effect, the preparation has low bioavailability and the like can be overcome, and the problems of low Bufalin content, inconvenient use, poor patient complicance and the like in the injectioncan be solved. Thus, the Bufalin is prepared into the dry powder inhalant, which has great prospect for developing new drug.
Owner:JIANGSU PROVINCE INST OF TRADITIONAL CHINESE MEDICINE
Medicine composition and gel for oral mucosa inflammatory pain and bacteriostasis and preparation method
ActiveCN111388500APromote healingObviously complementaryAntibacterial agentsOrganic active ingredientsOral ulcersIrritation
The invention discloses a medicine composition and gel for oral mucosa inflammatory pain and bacteriostasis and a preparation method. Bufalin, dyclonine, chitosan quaternary ammonium salt and epsilon-polylysine are used as the medicine composition to treat symptoms of oral ulcer and mucosa inflammatory pain, the medicine composition is a compound preparation according to the mechanism of pain on the surface of oral ulcer and pain causing base of inhibiting multiple microorganisms on the surface of the ulcer, the bufalin and the dyclonine are combined to quickly block pain conduction of exposednerve endings for a long time, food addition of non-western medicine antibiotics and combination of chitosan quaternary ammonium salt and epsilon-polylysine are adopted to effectively kill multiple pathogenic microorganisms on the surface of the ulcer, inflammatory irritation is further reduced, and the healing function of the wound ulcer is promoted.
Owner:陕西恒远生物科技有限公司 +1
High purity bufonis veneum direct oral decoction piece and preparation method thereof
InactiveCN107158039AAccurate doseImprove securityAmphibian material medical ingredientsPowder deliveryProduct inspectionMedicine
The invention discloses a high purity bufonis veneum direct oral decoction piece and a preparation method thereof. The bufonis veneum direct oral decoction piece is in single dose package with a specification of 1-60mg, and the bufonis veneum powder particle size is smaller than or equal to 50 meshes. Calculated on a dry product, the total amount of bufalin, cinobufagin and resibufogenin contained in the direct oral decoction piece is not less than 6.5% (g / g), the total ash is not more than 5.0%, and the acid-insoluble ash does not exceed 2.0%. Salmonella (10g) is not detected in the product, and bile salt resistant gram-negative bacteria is less than 10000cfu (1g). The bufonis veneum direct oral decoction piece is produced in workshops conforming to the "good manufacture practice of drugs". The preparation method includes: (1) raw material inspection; (2) primary crushing; (3) processing with wine; (4) filtering; (5) drying; (6) second crushing; (7) inner packing; (8) outer packaging; and (9) finished product inspection. Specifically, the steps (2)-(7) are carried out in a D grade clean production area, and the step (8) is conducted in a general production area. The bufonis veneum direct oral decoction piece is in single dose package, has the advantages of accurate dosage, controllable production process, good safety, and qualified microbial limit, the product is in accordance with the quality standards of direct oral drugs, and is suitable for direct oral taking.
Owner:四川仟源中药饮片有限公司
Method for microwave extracting fat-soluble toad venom by using skin of Bufo bufo gargarizans
ActiveCN101669970AHigh extraction rateEasy to separateAmphibian material medical ingredientsAntinoxious agentsToad VenomRetention time
The invention discloses a method for microwave extracting fat-soluble toad venom by using skin of Bufo bufo gargarizans, which comprises the following steps: using ethanol as extraction solvent, using microwave to dispel, heat and extract, using ultrafiltration membrane to filter and then concentrating the extraction solvent, and using liquid chromatogram technique to conduct separation and purification, wherein the extraction temperature breaks through the convention, is relatively higher but is still controlled within the lowest denaturation temperature, and the extraction time is shorter and less than one hour. Therefore, the denaturation of the fat-soluble toad venom is less, and the extraction rate is relatively higher during the extraction process; when the liquid chromatogram conducts separation and purification, the retention time of bufalin, cinobufagin and resibufogenin are respectively 7.594min, 10.103min and 10.741min, thus being capable of better separating and obtaining various fat-soluble toad venoms; the obtained bufalin, cinobufagin and resibufogenin has high purity which can reach 99%, and the impurity is little, therefore the obtained various fat-soluble toad venoms are more stable, and not easy to generate denaturation; and the extraction rate of the fat-soluble toad venom is more than 17%, and the highest extraction rate can reach 40%.
Owner:NINGBO UNIV
Applications of Bufalin in preparing preparation capable of realizing targeted inhibition on pancreatic cancer stem cells
InactiveCN107137411APotential mechanism against pancreatic cancer confirmedSuppression ratioOrganic active ingredientsAntineoplastic agentsSerum igeSerum free
The invention belongs to the technical field of medicines, relates to the novel medicinal application of the traditional Chinese medicinal preparation, namely, Bufalin, and in particular relates to applications of bufalin in preparing a preparation capable of realizing targeted inhibition on pancreatic cancer stem cells. The invention further provides a method for culturing Miapaca2 / GEM by adopting a serum-free suspension culture method, and thus the stem cell spheres with a high proportion are obtained. According to the scheme, from the aspect of tumor stem cells, the experiment shows that in the application of preparing the preparation capable of realizing targeted inhibition on pancreatic cancer stem cells of the traditional Chinese medicinal preparation, namely, Bufalin, the preparation can inhibit the self-renewal of the tumor stem cells, particularly, the preparation can inhibit the proportion of the tumor stem cells in the pancreatic cancer drug resistant cell line Miapaca2 / GEM, and thus the drug tolerance of pancreatic cancer is inverted.
Owner:FUDAN UNIV SHANGHAI CANCER CENT
Application of Bufalin-3beta-N-methoxyl-N-beta-D-heteroside in preparing cardiotonic drug
InactiveCN105030804AImprove securitySimple preparation processOrganic active ingredientsCardiovascular disorderDigoxinGlucoside
The invention belongs to the technical field of preparation of cardiotonic drugs, and discloses an application of Bufalin-3beta-N-methoxyl-N-beta-D-heteroside in preparing a cardiotonic drug. The Bufalin-3beta-N-methoxyl-N-beta-D-heteroside in preparing cardiotonic drug has the structure as shown in the formula I (the formula I is in the description). The researches made in the invention shows that Bufalin-3beta-N-methoxyl-N-beta-D-heteroside has obvious activity in inhibiting Na<+> / K<+>-ATP enzyme, higher cardiotonic activity than that of positive medicine digoxin, and higher selectivity index for alpha2 subtype than that of positive medicine digoxin. The Bufalin-3beta-N-methoxyl-N-beta-D-heteroside is high in safety, strong in cardiotonic effect and good officinal prospect, and the preparation technology is simple, low in cost and high in yield.
Owner:JINAN UNIVERSITY
Pharmaceutical composition for synergistically inhibiting liver cancer sorafenib drug resistance and application thereof
PendingCN111632132AGood anti-liver cancer effectImprove the efficacy of anti-liver cancerOrganic active ingredientsPeptide/protein ingredientsPharmaceutical drugCurative effect
The invention relates to the field of medicines, in particular to application of melittin and bufalin combination in preparation of a medicine for treating liver cancer, a pharmaceutical composition for synergistically inhibiting liver cancer sorafenib resistance and application of the pharmaceutical composition. The composition has the advantages that the melittin and the bufalin can play a goodanti-liver cancer role through different mechanisms, the anti-liver cancer curative effect can be improved through combined application of the melittin and the bufalin, the synergistic anti-liver cancer sorafenib drug resistance role is played, and the using effect is better than that of a single drug.
Owner:SHANGHAI CHANGHAI HOSPITAL
Nanometer granule prepn of bufanin albumin and its prepn process
ActiveCN1302809CReduce releaseImprove playbackOrganic active ingredientsPeptide/protein ingredientsSide effectHalf-life
The present invention relates to medicine technology, and is nanometer granular bufalin-albumin preparation as one new preparation form of bufalin and its preparation process. Bufalin has excellent effects of treating tumor, reversing chemotherapeutic drug resistance, inhibiting hepatitis B virus copying, etc. but high toxicity and short intracorporeal half life, forming no medicine preparation up to now. The nanometer granular bufalin-albumin preparation of the present invention has round shape of nanometer grains, narrow grain size distribution in the range of 50-250 nm, average grain size of 102 nm, liver targeting and delayed releasing, so that it has increased concentration in target organ for long time action, raised curative effect and lowered toxic side effect and may be used in preparing medicine for treating liver cancer and hepatitis B.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Pharmaceutical composition for treating cardiovascular disease and preparation method thereof
ActiveCN103156870AImprove protectionSignificant effectAnhydride/acid/halide active ingredientsCardiovascular disorderLactate dehydrogenaseCreatine kinase
The invention belongs to a field of medicament preparation, and relates to a pharmaceutical composition for treating cardiovascular disease and a preparation method thereof, especially to the pharmaceutical composition which contains drug-efficacy component groups capable of being absorbed into blood. The drug-efficacy component groups comprise: Japanese bufotaline, ginsenoside Re, ginsenoside Ra1, 1[beta]-hydroxy bufalin, ginsenoside Rb1, resibufogenin fine alcohol, ginsenoside Rc, ginsenoside Rb2, ginsenoside, ginsenoside Rd, bufalin, cholic acid, hyodeoxy cholic acid, cinobufagin, chenodeoxycholic acid and deoxycholic acid. The medicament has clear in vivo targets, has characteristics and advantages of multi-component multi-target effects, is good in protective effects for acute myocardial ischemia, and can reduce area of myocardial infarction and content of Lactate dehydrogenase and creatine kinase in serum.
Owner:HEHUANG PHARMA SHANGHAI +1
Bufalin (BUF)-carrying nano liposome modified by hyaluronic acid as well as preparation method and application of BUF-carrying nano liposome
InactiveCN111773185AImprove solubilityImprove permeabilityOrganic active ingredientsPharmaceutical non-active ingredientsTumor targetDocetaxel-PNP
The invention relates to the technical field of medicine, in particular to a bufalin (BUF)-carrying nano liposome modified by hyaluronic acid as well as a preparation method and application of the BUF-carrying nano liposome. A film dispersion method is combined with an ultrasonic method to prepare the liposome with a smaller particle size and dispersion uniformity, the hyaluronic acid is linked tothe DOPE phospholipid through chemical modification, and a dialysis bag method is used for purification. The solubility of the BUF can be improved, the tumor targeting effect can be enhanced, toxic and side effects can be reduced, the drug resistance of breast cancer cells to docetaxel (DCT) can be reversed, and new dosage form application is provided for the clinical application of the BUF.
Owner:SHANGHAI PUTUO DISTRICT CENT HOSPITAL
Preparation method of venenum bufonis extract and application thereof in preparation of anti-brain glioma medicine
InactiveCN105726578AHigh purityGood application effectAmphibian material medical ingredientsAntineoplastic agentsTraditional medicineVenenum bufonis
The invention relates to the technology of traditional Chinese medicine extraction and discloses a preparation method of a venenum bufonis extract, by which the venenum bufonis extract being higher than 95% in comprehensive content of bufalin, cinobufagin and resibufogenin can be prepared. The invention also discloses an application of the venenum bufonis extract being higher than 95% in the comprehensive content of the bufalin, cinobufagin and resibufogenin in preparation of an anti-brain glioma medicine.
Owner:赵婷
Preparation method for extracting cinobufagin and bufalin mixture from venenum bufonis
The invention relates to a preparation method for extracting a cinobufagin and bufalin mixture from venenum bufonis. The preparation method is characterized by comprising the following steps of: smashing the venenum bufonis into medium coarse powder, and then adding 70%-95% of ethanol for extraction; and carrying out silica gel column chromatography separation on an extracting solution to obtain the high-purity cinobufagin and bufalin mixture, wherein the content of the cinobufagin and bufalin mixture achieves more than 80%. The total content of the cinobufagin and bufalin mixture extracted by adopting the preparation method disclosed by the invention achieves more than 80%.
Owner:SHANDONG UNIV OF TRADITIONAL CHINESE MEDICINE
Methods of treating cancer
PendingCN112020362ADelayed progressGrowth inhibitionOrganic active ingredientsPharmaceutical delivery mechanismOncologyPharmacology
Owner:NEUPHARMA
Traditional Chinese medicine venenum bufonis extract and preparation method thereof
ActiveCN102512453BImprove extraction efficiencyExcellent transfer rateAmphibian material medical ingredientsAntineoplastic agentsMedicinal herbsGradient elution
Owner:北京协和制药二厂有限公司
Bufalin micelle nano-preparation and preparation method thereof
ActiveCN108295030AImprove physical and chemical propertiesGood water solubilityOrganic active ingredientsEmulsion deliveryPolymerMicelle
Owner:THE HONG KONG POLYTECHNIC UNIV SHENZHEN RES INST +1
Na+/k+ atpase inhibitors for use in the prevention or treatment of metastasis
PendingUS20220062317A1Enhanced signalOrganic active ingredientsAntineoplastic agentsATPaseEnzyme Inhibitor Agent
The invention relates to an Na+ / K+ ATPase inhibitor for use in the prevention or treatment of metastasis in a cancer patient defined by the presence of CTC clusters in the bloodstream. In certain embodiments the Na+ / K+ ATPase is a cardiac glycoside and is selected from: digitoxin, ouabain, convallatoxin, proscillaridin, lanatoside C, gitoformate, peruvoside, strophanthidin, metildigoxin, deslanoside, bufalin, digoxin and digoxigenin. The invention further relates to the use of nucleic acid agents inhibiting the expression of genes related to CTC cluster formation and maintenance.
Owner:UNIVERSITY OF BASEL
Nanometer granule prepn of bufanin albumin and its prepn process
ActiveCN1772291ALow costEasy to operatePeptide/protein ingredientsDigestive systemSide effectHalf-life
The present invention relates to medicine technology, and is nanometer granular bufalin-albumin preparation as one new preparation form of bufalin and its preparation process. Bufalin has excellent effects of treating tumor, reversing chemotherapeutic drug resistance, inhibiting hepatitis B virus copying, etc. but high toxicity and short intracorporeal half life, forming no medicine preparation up to now. The nanometer granular bufalin-albumin preparation of the present invention has round shape of nanometer grains, narrow grain size distribution in the range of 50-250 nm, average grain size of 102 nm, liver targeting and delayed releasing, so that it has increased concentration in target organ for long time action, raised curative effect and lowered toxic side effect and may be used in preparing medicine for treating liver cancer and hepatitis B.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com